- Home
- FRME vs VERA Comparison
FRME vs VERA Comparison
Compare FRME & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | VERA |
|---|---|---|
| Founded | 1893 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FRME | VERA |
|---|---|---|
| Price | $38.84 | $49.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $47.33 | ★ $67.67 |
| AVG Volume (30 Days) | 255.6K | ★ 1.8M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ 32.99 | N/A |
| EPS | ★ 4.00 | N/A |
| Revenue | ★ $649,589,000.00 | N/A |
| Revenue This Year | $13.83 | N/A |
| Revenue Next Year | $14.54 | N/A |
| P/E Ratio | $9.70 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $33.13 | $18.53 |
| 52 Week High | $45.62 | $50.16 |
Technical Indicators
Market Signals| Indicator | FRME | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 66.75 | 81.16 |
| Support Level | $36.99 | $40.38 |
| Resistance Level | $39.08 | $47.10 |
| Average True Range (ATR) | 0.74 | 3.45 |
| MACD | 0.25 | 1.26 |
| Stochastic Oscillator | 91.39 | 91.67 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.